Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda
Publication date: Available online 14 January 2020Source: The Lancet HIVAuthor(s): Oliver Ratmann, Joseph Kagaayi, Matthew Hall, Tanya Golubchick, Godfrey Kigozi, Xiaoyue Xi, Chris Wymant, Gertrude Nakigozi, Lucie Abeler-Dörner, David Bonsall, Astrid Gall, Anne Hoppe, Paul Kellam, Jeremiah Bazaale, Sarah Kalibbala, Oliver Laeyendecker, Justin Lessler, Fred Nalugoda, Larry W Chang, Tulio de OliveiraSummaryBackgroundInternational and global organisations advocate targeting interventions to areas of high HIV prevalence (ie, hotspots). To better understand the potential benefits of geo-targeted control, we assessed the extent...
Source: The Lancet HIV - January 15, 2020 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2019; 6: e737–49
Publication date: Available online 9 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 10, 2020 Category: Infectious Diseases Source Type: research
HIV-related stigma among health-care workers in the MENA region
Publication date: Available online 9 January 2020Source: The Lancet HIVAuthor(s): Tala Ballouz, Nour Gebara, Nesrine Rizk (Source: The Lancet HIV)
Source: The Lancet HIV - January 10, 2020 Category: Infectious Diseases Source Type: research
Women in Kenya face challenges to adherence
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): Christabel Ligami (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research
Highlights of the 17th European AIDS Conference
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): Philippa Harris (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research
People have the power
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research
Tough requirements for new antiretroviral drugs
Publication date: Available online 3 January 2020Source: The Lancet HIVAuthor(s): Carmen de Mendoza, Vicente Soriano (Source: The Lancet HIV)
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research
Influenza vaccine in pregnant women with HIV: are we there?
Publication date: Available online 3 January 2020Source: The Lancet HIVAuthor(s): Sharon Nachman (Source: The Lancet HIV)
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research
Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
This study assessed the immunogenicity and safety of different dosing schedules of inactivated influenza vaccine in pregnant women living with HIV in South Africa.MethodsIn this double-blind, randomised, controlled trial, we recruited pregnant women with HIV from seven antenatal clinics in Soweto, South Africa. Pregnant women were eligible if they were aged 18–38 years, infected with HIV, and had an estimated gestational age of 12–36 weeks. Women were randomly assigned (1:1:1), using a computer-generated randomisation list, to receive inactivated influenza vaccine containing 15 μg of each of the three seasonal influen...
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
This study is registered with ClinicalTrials.gov, NCT02217904, and EudraCT, 2014-002192-28.FindingsBetween Sept 17, 2015, and May 11, 2017, we enrolled 30 participants (six per panel). Islatravir was generally well tolerated. 27 (90%) participants had 60 adverse events after receipt of drug, of which 21 (35%) were deemed to be drug related. The most common (n>1) drug-related adverse events were headache (in nine [30%] participants) and diarrhoea (in two [7%]). No serious adverse events were reported, and no participants discontinued due to an adverse event. Plasma islatravir pharmacokinetics and intracellular islatravir-tr...
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research
No excuses left to delay opioid agonist treatment roll-out
Publication date: Available online 23 December 2019Source: The Lancet HIVAuthor(s): Ruslan Malyuta, Reinhard M Krausz (Source: The Lancet HIV)
Source: The Lancet HIV - December 24, 2019 Category: Infectious Diseases Source Type: research
Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study
Publication date: Available online 23 December 2019Source: The Lancet HIVAuthor(s): Jiale Tan, Frederick L Altice, Lynn M Madden, Alexei ZelenevSummaryBackgroundAs HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverage among PWID, we did an optimisation assessment using current OAT procurement and allocation, then modelled the effect of increased OAT scale-up on HIV incidenc...
Source: The Lancet HIV - December 24, 2019 Category: Infectious Diseases Source Type: research
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Robert C Bollinger, Chloe L Thio, Mark S Sulkowski, Jane McKenzie-White, David L Thomas, Charles FlexnerSummaryThe first long-acting formulations of HIV drugs are undergoing regulatory review for use in maintenance of viral suppression in people with HIV. Although these novel drug formulations could contribute greatly to HIV treatment and prevention efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact, particularly in populations with high burdens of both HIV and HBV. An urgent need for greater inv...
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research
Adherence among post-partum women living with HIV
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Rachel K Scott (Source: The Lancet HIV)
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research
Trends in post-partum viral load among women living with perinatal HIV infection in the USA: a prospective cohort study
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Kunjal Patel, Brad Karalius, Kathleen Powis, Deborah Kacanek, Claire Berman, Anna-Barbara Moscicki, Mary Paul, Katherine Tassiopoulos, George R Seage, HIV/AIDS Cohort Study (PHACS)SummaryBackgroundSmall studies reported poor post-partum outcomes among young women living with perinatal HIV infection who are now ageing into adulthood and becoming pregnant. For targeted clinical intervention, we sought to identify women in this population at risk of poor post-partum virological control.MethodsWe abstracted data on pregnancy history for women l...
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research
